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Within the past decade, the use of statins as a potential cancer treatment has been investigated. 
However, the molecular mechanisms involved in their anti-oxidant, anti-proliferative and anti-
cancer effects remain elusive. In our study, we investigated the involvement of downstream 
mevalonate products that mediate the anti-oxidant and anti-proliferative effects of Atorvastatin 
(Ato) in hepatocellular carcinoma, HepG2 cells. A more soluble form of Ato was prepared and 
the cells were treated with 678.8µg/ml (IC50) for 48hrs (MTT assay). The effect of Ato on cell 
viability and metabolic activity was determined using MTT and ATP assays; oxidative status 
using TBARS, Griess, GSH and CYP3A4 assays; cellular death using LDH,  ELISA, and 
caspase -3/7, -8, and 9 activity. Additionally, protein expression of pAKT, AKT, pGSK3-(α/β), 
p53, NF-κB, and IKK-β was assessed by western blotting. Ato induced a dose-dependent 
decrease in cell viability with a concomitant depletion of intracellular ATP levels (p=0.005). 
Interestingly, Ato significantly decreased lipid peroxidation (p=0.0097) whilst increasing nitrite 
levels (p=0.001). Atorvastatin significantly decreased glutathione levels (p=0.0003), whereas 
the enzyme activity of CYP3A4 was significantly increased (p=0.0079). Collectively, these 
results demonstrate the anti-oxidant properties of Ato. The anti-proliferative, cytotoxic, and 
apoptotic effects  of Ato were depicted by a significant increase in LDH levels (p=0.0002), 
induction of the intrinsic apoptotic pathway evidenced by a significant elevation in -9 activity 
(p<0.0001) and caspase-3/7 (p=0.0003), a significant decrease in Caspase-8 activity (p=0.0025) 
and TNF-α concentration (p=0.0105), and a significant increase in IL-6 concentration 
(p=0.0012) which correlates with the significant reduction in NF-κB protein expression 
(p=0.013). Protein expression of pGSK3-(α/β) (p=0.0338), and p53 (p=0.0032), were 
significantly up-regulated; whereas protein expression of pAKT (p=0.0035), AKT (p=0.0077), 
and IKK-β (p=0.0094) were significantly reduced. In conclusion our data shows that Ato 











Statins are a well-known class of drugs used in the treatment of lipid-associated disorders, 
specifically hypercholesterolemia. They function by impeding cholesterol synthesis via 
inhibition of the key enzyme in the pathway, 3-hydroxy-3-methyl-glutaryl-coenzyme-A 
reductase (HMGCR) (Chan et al., 2003b). It is through this mechanism that statins have the 
ability to reduce the risk of  stroke, myocardial infarction and death (Strandberg et al., 2004). 
The pleiotropic effects of statins include, improvement of endothelial dysfunction, improve 
atherosclerotic plaque stability, impeding thrombogenic response, as well as decrease 
inflammation and oxidative stress (Liao and Laufs, 2005).  Statins play an instrumental role in 
cardiovascular medicine. Evidence from clinical trials suggests that with statin therapy there are 
decreased cardiovascular-related deaths (Wright et al., 1994, Schwartz et al., 2001, Shepherd et 
al., 1995). Atorvastatin (Ato) is a synthetic derivative of mevalonate and pyridine (Matusewicz 
et al., 2015). The structure of Ato consists of a pyrrole and heptanoic acid derivative which 
resembles HMG-CoA. Hydrophobic statins like Ato predominantly undergo metabolism via the 
cytochrome P-450 3A4  enzyme family (Schachter, 2005). 
 
Cancer is the second leading cause of death in the world, after cardiovascular disease (Ma and 
Yu, 2006). Due to the significant disease burden and related mortality, the need for better 
treatment options with reduced side-effects is essential. Several hallmarks contribute to the 
complexity of tumour growth and progression. These include, withstanding cell death, 
maintaining proliferative signalling, inducing angiogenesis, enabling replicative immortality, 
evasion of growth suppressors, and activating invasion and metastasis (Hanahan and Weinberg, 
2011)  Apoptosis is a type of programmed destruction of the cell that ultimately leads to death 
(Hengartner, 2000). It is through this process that cells maintain equilibrium between 
proliferation and death (Schwartzman and Cidlowski, 1993). Survival of cancer cells occurs 
through their ability to evade apoptosis (Hanahan and Weinberg, 2011). Statins have been 
shown to exert apoptotic effects in vascular smooth muscle cells (Erl, 2005). The apoptotic 
effects of Cerivastatin through geranylgeranyl pyrophosphate (GGPP) inhibition have been 
depicted in vivo (Johnson et al., 2004). Furthermore, the apoptotic-inducing effects of 
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Lovastatin and Simvastatin via the extrinsic pathway were illustrated in prostate cancer cells 
(Hoque et al., 2008). 
 
Numerous signal transduction pathways have been identified in normal cellular function. 
Transformation of normal cells to a cancerous state is a result of aberrant signalling. 
Phosphoinositide 3-kinases (PI3Ks) are a part of a family of lipid kinases that promote Protein 
Kinase B (Akt) recruitment via phosphorylation of phosphatidylinositol-3, 4, 5-triphosphate 
(PIP3) (Cantley, 2002). Consequently cell survival, proliferation and differentiation are 
augmented. Cancer development through amplified PI3K/Akt-mediated signalling is well 
documented. A few targets of this pathway include Bax, Bcl-2, NF-κB, ubiquinone, cell cycle 
regulators such as p21, and glycogen synthase kinase-3 (GSK-3) (Chang et al., 2003, Luo et al., 
2003). An important mechanism of this pathway is apoptotic inhibition; hence novel 
chemotherapeutic agents that target this cascade may be a promising approach. 
 
The mevalonate pathway is responsible for production of a range of end products that have 
essential roles in cell function. Included in these products are isoprene units that encompass 
sterol and nonsterol compounds like dolichol, ubiquinone, cholesterol, GGPP, and farnesyl 
pyrophosphate (FPP) (Goldstein and Brown, 1990). Isoprenoids are responsible for Ras and 
Rho prenylation (Kamat and Nelkin, 2005). Prenylation of these GTPase proteins result in 
reactive oxygen species (ROS) oxysterol production, inhibition of endothelial nitric oxide 
synthase (eNOS), as well as activation of the PI3K/Akt pathway, which collectively contribute 
to tumourigenesis (Stryjkowska-Gora et al., 2015). Recent evidence indicates that Atorvastatin, 
Fluvastatin and Simvastatin induce lymphoma cell death via activation of anti-apoptotic 
molecule, Bcl-2; increased intracellular ROS levels; p38 activation and suppression of Akt and 
ERK pathways (Qi et al., 2013). However, the exact molecular mechanisms involved in statin-
mediated cancer cell death are intricate and need to be explored further. 
 
1.1.1 Study Rationale and aims 
 
In vitro investigations have indicated the potential of statins as anti-cancer agents (Agarwal et 
al., 1999, Aprigliano et al., 2008, Kanugula et al., 2014, Stryjkowska-Gora et al., 2015). 
Considering that the majority of studies are either preclinical or observational clinical studies, 
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the need arises to investigate statins further. Understanding the underlying mechanisms of 
statins and how they may exert their effects prior to an in vivo or clinical study is essential. 
 
The liver plays a fundamental role in carbohydrate, protein, lipid and xenobiotic metabolism.  
Atorvastatin is primarily metabolised by the liver. Hepatocellular carcinoma (HCC) is a primary 
malignancy of the liver. The liver derived HepG2 cells are often used as HCC model as they 
represent a pure cell line due to the absence of viral infection. It is also known to express 
HMGCR (Molowa and Cimis, 1989). Atorvastatin was selected for this study as it is the most 




The aim of this study was to determine the effect of Ato on cellular 
proliferation/metabolic activity, oxidative status, and elucidate the mode by which 
Ato exerts its effects in Hepatocellular Carcinoma, HepG2 cells. 
1.1.3  Objectives of this study were designed to: 
 
 Evaluate cytotoxicity (MTT assay) and apoptotic regulators such as caspase (-8, -9, 
and -3/7) activity, NF-κβ, Iκκ-β, and p53. 
 Measure oxidative stress parameters via evaluation of MDA, nitrite levels, GSH, and 
CYP3A4 activity. 
 Assess the inflammatory status by measuring cytokine levels of TNF-α, IL-6 using 
ELISA 




Atorvastatin exerts anti-oxidant, anti-inflammatory, and apoptotic effects via inhibition of the 





1.2 LITERATURE REVIEW 
1.2.1 Statins 
 
Atorvastatin (Ato), trade name Lipitor, is one of the most commonly prescribed drugs in the 
treatment of heart disease (Puntarulo and Cederbaum, 1998). The differentiating factors of 
statins lie in their pharmacokinetic properties (Liou and Storz, 2010, Kanugula et al., 2014). 
Their chemical structures play important roles in water solubility, which influences absorption, 
metabolism, distribution and excretion. Atorvastatin is a synthetic mevalonate derivative. Its 
structure (Figure 1.1) is comprised of three main groups, these include two hydrophobic 
hydroxyl hexahydro naphthalene ring structures and the HMGC equivalent (Halliwell and 
Chirico, 1993). Metabolism of Ato mainly occurs in the liver, by either an acyl glucuronide 
intermediate or coenzyme-A dependent pathway, where biotransformation of the acid 
component to a lipophilic lactone occurs. The CYP3A4 enzyme is responsible for further 
metabolism of Ato and its associated lactone form, whilst CYP2C8 metabolises it to a lesser 
extent. Hydrolysis of the Ato lactone to its acidic form occurs by paraoxonases and esterases or 
nonenzymatically (Liu et al., 2002, Dröge, 2002).  
 
 




1.2.1.1 Mode of action of statins in Coronary Artery Disease 
Cholesterol biosynthesis is regulated by the rate-limiting enzyme- HMG-CoA reductase 
(HMGCR). The reduction of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to 
mevalonate is catalysed by this enzyme. Statins mimic the HMG-CoA molecule, thus allowing 
competitive inhibition of HMGCR. This slows down or decreases the rate at which mevalonate 
is produced. Statins are used as primary prevention of strokes and heart attacks in 
cardiovascular disease (Rosa et al., 2014).  
 
Atorvastatin is a synthetic compound that reduces de novo cholesterol synthesis and increases 
the expression of hepatic low density lipoprotein (LDL) receptors (Goldstein and Brown, 1990). 
As a result, LDL catabolism by hepatocytes is increased, and blood LDL-cholesterol is 
decreased (Nawrocki et al., 1995). Triglyceride blood levels are also reduced by Ato with a 
slight increase in high density lipoprotein (HDL)-cholesterol levels.  
 
1.2.1.2 Mechanism of action of statins and cancer 
 
Mevalonate production serves as a precursor of many sterols. Upon inhibition, various 
downstream metabolites are also affected (Figure 1.2). Isoprenoid production is an essential 
component in posttranslational modification of numerous proteins, including Farnesyl 
Pyrophosphate (FPP) and Geranylgeranyl pyrophosphate (GGPP) (Yeganeh et al., 2014). Ras 
and Rho protein GTPases are prenylated by isoprenoids. This facilitates their translocation to 
the cell membrane, which allows intracellular signalling to occur. The potential antioxidant 
properties of statins involve reactive oxygen species (ROS) inhibition via suppression of 
NADPH oxidase activity (Chen et al., 2012). The anti-inflammatory properties of statins have 
been depicted via effects on C-reactive protein (CRP) (Jialal et al., 2001); tumour necrosis 
factor α (TNF α) (Bruegel et al., 2006); interleukin-6 and -8 (IL-6, IL-8) (Park et al., 2008b); 





Figure 1.2: Mechanism of action of Atorvastatin: inhibits cholesterol synthesis (prepared by 
author: Docrat, 2016). HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A, HMGCR: 3-
hydroxy-3-methyl-glutaryl-coenzyme A reductase, PP: Pyrophosphate, ROS: Reactive oxygen 
species, eNOS: endothelial nitric oxide synthase, NADPH: Nicotinamide adenine dinucleotide 
phosphate. 
 
1.2.1.3 Epidemiological link between HMG-CoA reductase inhibitors and cancer 
 
In the past 15 years, there has been an exponential increase in the use of statins resulting in their 
long term safety becoming more apparent. Initially, concerns regarding decrease in serum 
cholesterol leading to increased rates of cancer were raised. Evidence suggests a possible 
association between low serum cholesterol and cancer associated mortality among men (Jacobs 
et al., 1992). Thereafter, concern that statins have intrinsic carcinogenic properties existed. The 
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adverse outcomes of statin use originated from studies in animal models as well as 
epidemiological data in humans. The potential carcinogenicity of statins on rodents was 
reviewed and concluded that lipid-lowering drugs should be avoided unless patients are at high 
risk of coronary heart disease (Newman and Hulley, 1996). Additionally,  human cohort studies 
supported this observation (Jacobs et al., 1992). The majority of the information relating to the 
impact of statins on cancer was obtained from observational studies; these results could be 
distorted by numerous factors. Confounding variables, such as pre-existing cancer, concurrent 
statin and cardiovascular treatment (e.g.: acetylsalicylic acid), high body mass index (BMI), 
elderly patients with a sedentary lifestyle, incorrect feeding, frequent dependence on tobacco, 
and their retrospective nature limited these studies. These factors influence the risk of cancer to 
a different degree.  
 
Despite the anxiety caused by these studies, other studies showed no significant increase in 
cancer mortality (Law and Thompson, 1991, Nielsen et al., 2012) Reassurance was provided 
regarding the risk of cancer from statin use in long-term studies on secondary prevention of 
coronary artery disease with statins (Pedersen et al., 2000). Several studies have affirmed the 
safety of statins, demonstrating no increase in cancer incidence with statin usage (Delgado and 
Leon, 2010, Lakha et al., 2012, Lee et al., 2011, Beg et al., 1993, Cantley, 2002, Mansouri et al., 
2013, Wang et al., 1996, Ng et al., 2011, Beg and Baltimore, 1996, Beg and Baldwin, 1993).  
 
1.2.1.4 Biochemical effects of statins 
 
Although statins have proved to be therapeutic and preventative agents in cardiovascular 
disease, recent interests have emerged in their use as anti-tumour agents. The basis of these 
interests lies in the preclinical evidence of their pro-apoptotic, anti-proliferative and anti-
invasive properties. Mevalonate and its downstream products, which are reduced by statins, 
have critical roles in cellular functions such as cell signalling, membrane integrity, cell cycle 
progression, and protein synthesis (Chan et al., 2003a). Tumour initiation, growth and 
metastasis can therefore be controlled in cells treated with statins due to perturbations of these 
processes. 
 
The anti-proliferative effects of HMG-CoA reductase inhibitors have been shown by tumour 
cell synchronisation via blocking of the G1-S phase in the cell cycle (Keyomarsi et al., 1991). 
Addition of mevalonate reverses this effect. Lovastatin has been shown to inhibit cell growth 
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(DeClue et al., 1991). Evidence suggests that HMG-CoA reductase inhibitors exert anti-
proliferative effects via cell cycle arrest due to increase mRNA and protein expression in two 
cyclin-dependant kinase (CDK) inhibitors, p21 and p27 (Denoyelle et al., 2001, Law and 
Thompson, 1991). Apoptotic induction has been shown in human acute myeloid leukaemia cells 
treated with lovastatin (Xia et al., 2001). Studies also show that lovastatin increased expression 
in proapoptotic protein, Bax, and decreased expression in the anti-apoptotic protein, Bcl-2 
(Agarwal et al., 1999). Statins also induce apoptosis via activation of caspases-3, -8 and, -9, in 
human myeloma tumour cells (Cafforio et al., 2005). Atorvastatin has been shown to down-
regulate the pro-apoptotic protein, Bim, in endothelial progenitor cells (Urbich et al., 2005). 
Statins do have cytotoxic potential; however, the exact mechanism by which statins exert their 
effects is yet to be determined.   
 
1.2.2 Liver cancer  
 
Cancer is one of the leading causes of morbidity and mortality, with an approximated 14 million 
new cases and 8.2 million cancer-related deaths in 2012 worldwide (Stewart and Wild, 2016). 
New cases are expected to increase by 70% in the next 2 decades. Liver cancer remains the fifth 
most common in men and the eighth most common in women across the globe. Hepatocellular 
Carcinoma (HCC), a type of liver cancer, is the most common. Infections like Hepatitis B or C 
usually result in HCC. Other risk factors include alcohol consumption, tobacco usage and 
metabolic toxins like aflatoxin (Emerit, 1994).  
 
1.2.2.1 HepG2 cells 
 
The liver, being the hub of metabolism, is central to xenobiotic metabolism. The HepG2 cell 
line is liver derived and its detoxification abilities are attributed to inducible phase I & II 
enzymes. According to Mersch-Sundermann, HepG2 cells reflect xenobiotic metabolism in the 
human body to a greater extent in comparison to conventional cell lines that are metabolically 
incompetent (Mersch-Sundermann et al., 2004). Hence, the use of HepG2 cells for detection of 





1.2.3 Reactive oxygen species (ROS) 
 
1.2.3.1 Free Radicals  
 
Free radicals are molecules containing single or multiple unpaired electrons and can exist 
independently (Halliwell and Chirico, 1993). Oxygen-derived radicals have both hazardous and 
beneficial roles in cell functioning. Free radicals include, superoxide (O2-·) and related reactive 
oxygen species (ROS) as well as nitric oxide (NO·). These radicals may be sourced from, but 
not limited to, the mitochondrial electron transport chain (ETC), NADPH-oxidase, xanthine 
oxidase, NO synthase, and intracellular xenobiotic mechanisms (CYP450) (Chen et al., 2003, 
Dröge, 2002, Liu et al., 2002). Carcinogenesis may occur as a result of free radicals by various 
means. These include promoting cell growth by activation of proliferative pathways, preventing 
apoptosis as well as inducing DNA damage and inhibition of repair mechanisms (Federico et 
al., 2007). 
 
Cellular maintenance of redox-signalling is essential for growth and proliferation. Upon ROS 
exposure, redox homeostasis is established to prevent oxidative damage (Dröge, 2002). The 
concentration of free radicals is determined by the oxidant-antioxidant balance. It is well 
established that tumourigenesis is promoted by oxidative stress as a result of an imbalance 
between oxidant-antioxidant systems (Ambrosone, 2000, Emerit, 1994, Klaunig et al., 1998, 
Storz, 2005). Numerous studies indicate the antioxidant properties of statins (Davignon et al., 




Antioxidants are defined as substances that are able to inhibit oxidation of substrates, at 
relatively low concentrations (Halliwell and Gutteridge, 2015). These include the enzymes 
glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase, as well as other 
compounds that are non-enzymatic like ascorbic acid and glutathione (GSH) (Dröge, 2002). 
 
Glutathione plays an important role in protecting the cell from free radical and peroxide 
damage. The reduction of hydrogen peroxide (H2O2) and lipid hydroperoxides to water is 
catalysed by the GPx enzyme, whilst GSH functions as an electron donor (Ott et al., 2007, 
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Reuter et al., 2010) Following conversion of GSH to its oxidised form glutathione disulphide 
(GSSG), glutathione reductase (GR) recycles GSSG back to GSH which prevents depletion 




Figure 1.3: Antioxidant activity of GSH (prepared by author: Docrat, 2016) 
 
1.2.3.3 Cytochrome P450 3A4 
 
Cytochrome P450 (CYP450) enzymes are a superfamily of haem-containing mono-oxygenases 
that have essential roles in biotransformation and detoxification. They are located within the 
endoplasmic reticulum in majority of human tissues (Zangar et al., 2004). Exogenous 
substances e.g., drugs or carcinogens undergo oxidative metabolism by CYPs. The catalytic 
mechanism of detoxification by CYPs involves phase I reactions where xenobiotics are 
modified to promote phase II reactions (Westerink and Schoonen, 2007). In the liver, the 
CYP3A subfamily is most abundant, making up approximately half of the CYP content (Ding 
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and Kaminsky, 2003, Pan et al., 2010). CYP3A4 activity is known to promote ROS production 




Apoptosis is the physiological process of programmed cell death. This process is crucial in 
regulating cell numbers during development by eliminating cells that are damaged, redundant or 
irreparable (Schwartzman and Cidlowski, 1993). This sequential process is characterised by 
distinct morphological changes that lead to disintegration and destruction of the cell. During 
apoptosis, two distinct phases are involved in programming cell death. The first phase consists 
of cytoplasmic and nuclear condensation, resulting in membrane breakage and release of 
structurally intact organelles. During the second phase, phagocytosis of the apoptotic bodies 
occurs by neighbouring cells. In contrast to necrosis, apoptosis prevents an inflammatory 
response via maintenance of organelle integrity which allows for minimal intracellular content 
leakage (Chen et al., 2012). Disturbances of the apoptotic mechanism are implicated in various 
pathological conditions, ranging from auto-immune diseases to degenerative disorders and 
cancer (Adams, 2003, Bours et al., 2000). 
  
Apoptosis is driven by caspases, a group of aspartate-specific cysteinyl proteases. The initiator 
caspases are responsible for activation of a second group of caspases, the executioners, by 
proteolytic cleavage (Luzzi and Marletta, 2005). The caspase enzymes have active cysteine sites 
which function in cleavage of substrates containing aspartate residues. Caspases are maintained 
as inactive zymogens with three domains: the N-terminus prodomain, a p10 and a p20 domain 
located in a mature caspase. Cleavage of zymogens between the p20 and prodomain or between 
the p10 and p20 domains, allows for caspase activation. The morphological changes of cells 
undergoing apoptosis are a result of the executioner caspases . In mammalian cells, two major 
apoptotic pathways exist: the intrinsic mitochondrial-mediated pathway and the extrinsic death 
receptor-mediated pathway (Figure 1.4). Control of these pathways is tightly maintained by a 







1.2.4.1 The intrinsic pathway of apoptosis 
 
The intrinsic apoptotic pathway is commonly known as mitochondrial apoptosis due to its 
dependence on factors released from the mitochondria. Activation of this pathway occurs by 
various cellular stressors including, deprivation of growth factors, disruption of the 
cytoskeleton, accumulation of unfolded proteins, insufficient cytokine support, damaged DNA, 
hypoxia, amongst others (Adams, 2003, Lalier et al., 2007). Mitochondrial membrane 
permeabilisation is controlled by the Bcl-2 family of proteins (Lalier et al., 2007). This step is a 
crucial for release of apoptotic proteins from the mitochondria. When mitochondrial membrane 
integrity is lost, pro-apoptotic proteins including Smac/DIABLO, Endonuclease G, Caspase 
Activated DNase (CAD) and AIF (Apoptosis-Inducing Factor) are released (Schimmer, 2004). 
Caspase-9 activation is energy dependent (Zangar et al., 2011) In a resting cell, both caspase-9 
and Apaf-1 exist as cytosolic, inactive monomers. When the cell experiences stress, 
mitochondrial release of cytochrome c occurs. Cytochrome c binds to Apaf-1, leading to 
recruitment of pro-caspase 9 and apoptosome formation (Figure 1.5). Initiator caspase 9 is 
activated and proteolytically cleaves the zymogens of executioner caspases, -3, -6, and -7 




Figure 1.4: Schematic representations of the main molecular pathways leading to apoptosis 
(Favaloro et al., 2012) 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
1.2.4.2 The extrinsic pathway of apoptosis 
 
The extrinsic apoptotic pathway is triggered by transmembrane death receptor-mediated 
reactions. The tumour necrosis factor (TNF)-α death receptor family is a well-documented 
mechanism for activation of the extrinsic pathway. Apoptotic signals are known to be induced 
by TNF-related apoptosis-inducing ligand (TRAIL)-R1/R2, TNF-α receptor 1 (TNF-R1), Fas 
(CD95)-R, CAR-1, and DR3, which form part of the TNF- α family (Reed, 1999). The receptors 
of this family are known as the death domain (DD), which is composed of a cysteine rich 
extracellular domain and a cytoplasmic DD (Jucker et al., 2002). Death domains function in 
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signal transmission from the outer surface of the cell to intracellular signalling pathways. 
Activation of the extrinsic pathway via ligand-receptor binding has been extensively 
characterised with Fas ligand (Fas-L)/Fas-receptor (Fas-R) and TNF/TNF-R models (Jucker et 
al., 2002, Lin et al., 1999, Fry, 2001, Rubio-Moscardo et al., 2005). Death receptors cluster at 
the cell membrane where homologous trimeric ligands bind. Cytoplasmic adaptor proteins and 
their corresponding DDs are recruited. Fas associated protein and its DD (FADD) is recruited 
by Fas-L/Fas-R, and TNF-R1 associated protein and its DD (TRADD) with FADD and RIP are 
recruited by TNF/TNF-R (Krasilnikov et al., 1999, Mistafa and Stenius, 2009). Additionally, 
FADD contains the death effector domain (DED). The binding of FADD to a homologous DED 
found on procaspase-8, results in the formation of a death inducing signalling complex (DISC) 
which catalyses caspase-8 cleavage and activation (Zhou et al., 2000). Apoptosis is then 
executed by subsequent cleavage and activation of effector procasapase-3/7. Insufficient 
caspase-8 activation at the DISC, promotes mitochondrial amplification of death signals through 
the intrinsic pathway (Figure 1.5), mediating full caspase activation (Aprigliano et al., 2008, 
Minichsdorfer and Hohenegger, 2009).  
 
 
Figure 1.5: Induction of apoptosis in malignant cells due to novel chemotherapeutic agents that 






Necrosis is a type of cell injury that leads to premature cell death by autolysis in living tissue 
(Proskuryakov et al., 2003). External factors which may result in necrosis include trauma, toxins 
or injury that causes unregulated digestion of cell components. Usually, the effects of apoptosis 
are beneficial to the organism whilst necrotic effects are detrimental and could possibly be fatal 
due to harmful chemicals released. In necrosis, receptor activation leads to loss of integrity in 
the cellular membrane as well as liberates products of cell death into the extracellular space 
(Proskuryakov et al., 2003). Due to this, an inflammatory response is initiated in nearby tissue 
which prevents elimination of dead cells by phagocytosis (Schwartzman and Cidlowski, 1993). 
 
1.2.6 Role of PI3K/Akt signalling pathway in apoptosis and cell survival 
 
Protein Kinase B/Akt is a well-recognised cell cycle regulator (Luo et al., 2003). Many 
disorders, including cancer are associated with aberrant activation of this kinase (Datta et al., 
1997, McCubrey et al., 2007). Cytokine-specific receptor binding allows for lipid 
Phosphatidylinositol 3-Kinase, (PI3K), activation which occurs via two mechanisms. The first 
involves activation of Ras protein GTPase. PI3K consists of a regulatory (p85) and catalytic 
(p110) subunit. The second mechanism involves docking of the p85 subunit at the tyrosine 
residue, which results in p110 recruitment. (Lakha et al., 2012, Mansouri et al., 2013). 
Phosphatidylinositol (4, 5)-biphosphate (PIP2) is phosphorylated by PI3K to form 
phosphatidylinositol (3, 4, 5)-triphosphate PIP3 (Cole, 1986b, Cole, 1986a). 
Phosphatidylinositol dependent protein kinase 1 (PDPK1) is activated by PIP3 and results in Akt 
recruitment to the lipid-rich plasma membrane. Nuclear translocation of Akt is essential for cell 
proliferation and anti-apoptosis (Chen et al., 2003). Signalling initiated by PI3K is primarily 
mediated by Akt and alteration to downstream substrates in this pathway may cause oncogenic 
transformation. Examples of PI3K substrates include IKK-beta, nuclear factor- ĸB (NF- ĸB), 
inhibitor of apoptosis proteins (IAPs), Bax, Bcl-2, p21, and phosphorylated glycogen synthase 
kinase-3-α/β (pGSK-3-α/β) (Figure 1.6). These substrates play important roles in inhibition of 
apoptosis and cell cycle progression (Ng et al., 2011, Cantley, 2002). PI3K activity is associated 
with numerous human tumours, including melanomas, lung cancer, breast cancer and 






Figure 1.6: Inhibitory effect of statins on mevalonate and its downstream effects on PI3K/AKT 
signalling pathway (prepared by author: Docrat, 2016) 
 
1.2.7 Forkhead Box (FOXOs), c-Myc and the cell cycle 
 
A requirement for higher organism development is increased complexity. This is evident from 
the regulatory role played by the Forkhead box (FoxO) family. Thus far, four isoforms of FoxO 
have been identified in mammalian cells (FoxO1, FoxO3a, FoxO4 and FoxO6) (Cole, 1986b). A 
conserved evolutionary feature of FoxOs, despite their diversification, is their function as 
downstream effectors of PI3K/Akt (Escot et al., 1986). At the molecular level, Akt directly 
represses FoxO through phosphorylation, promoting its export from the nucleus, reduced 
transactivation activity and proteosomal degradation (Little et al., 1983, Cole, 1986b, Amati et 
al., 1998, Freytag, 1988). Deregulation of these kinases and PKB have been frequently observed 
in proliferative disorders and may contribute to tumourigenesis (Kulinsky, 2007, Dennis et al., 
2002). Numerous regulators of the cell cycle are controlled by FoxO, resulting in its important 
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role in regulating cell cycle senescence. Inhibition of PI3K in primary mouse embryo fibroblasts 
using chemical inhibitors can induce cell cycle arrest through FoxO-induced p27Kip1 expression, 
similar to that of cellular senescence (Howe, 2007). Further evidence of FoxOs role in cellular 
senescence is provided by an in vivo study that demonstrates repression of the PI3K/Akt 
signalling pathway with subsequent FoxO induction (Coussens and Werb, 2002). It can be 
assumed that cancer cells have repressed levels of FoxO3a as studies show that re-introduction 
of FoxO3a results in tumour cell death (Suganuma et al., 1999). One of the key pathways 
involved in activation of the cell cycle is the Wnt pathway. Cancer cell entry into the cell cycle 
is regulated by the Wnt pathway via activation of c-Myc, cyclin D and p53 (Sun et al., 2010, 
Kanugula et al., 2014, Xie et al., 2014, Wassmann et al., 2002). Studies suggest convergence of 
the PI3K/Akt/mTOR and Wnt pathways in regulation and progression of the cell cycle through 
the G0/S phase in cancer cells (Wang et al., 2008). 
 
The c-Myc gene is activated in human cancers via various mechanisms. C-Myc, a member of 
the Myc family of proteins, is known for its ability to regulate proliferation and apoptosis in 
normal cells. Through various mechanisms, deregulation of Myc-proteins occurs, resulting in 
one-third of human cancers. Normal c-Myc gene expression is under immaculate control. 
Formation of lymphoid malignancies are promoted by juxtaposing translocations of the c-Myc 
proto-oncogene (Cole, 1986b). Up-regulation of the c-Myc gene occurs in various cancers 
including lung and breast carcinomas (Little et al., 1983, Escot et al., 1986). Initial studies 
implicated c-Myc in the G0/G1 phase of the cell cycle (Freytag, 1988). Further insight was 
provided on the function of c-Myc upon CDK inhibitors, CDKs and cyclins emergence (Figure 
1.7) (Amati et al., 1998). C-Myc and cyclin-D1 function in S-phase entry of the cell cycle 
(Figure 1.7). Cyclins are up-regulated when c-Myc is activated (Cole, 1986b). Therefore, c-Myc 




Figure 1.7: Cell cycle regulation (prepared by author: Docrat, 2016) 
 
1.2.8 PI3K/Akt and cell cycle progression 
 
P21Cip1 is a potent cyclin-dependent kinase inhibitor (CKI). Binding of p21Cip1 to Cdk4/cyclin D 
and Cdk6/cyclin D complexes, induces kinase activity from early G1-until the middle of S-
phase. This inhibitory process is prevented by PI3K/Akt via p21 phosphorylation (Sherr and 
Roberts, 1999). Cyclin D1, a key player in progression of the cell cycle, is strongly activated by 
the PI3K/Akt pathway. Numerous proteins are phosphorylated and degraded by 
active/phosphorylated GSK-3(α/β) which inhibits the activity of their downstream targets cyclin 
D; c-Myc and glycogen synthase (Cantley, 2002, Woodgett, 1994). GSK-3(α/β) activation 
regulates the protein levels of cyclin D1 which allows for its stabilisation. Apoptotic regulation 
by GSK-3(α/β) is controversial; however studies have shown that GSK-3(α/β) overexpression 




1.2.8.1 PI3K/Akt and NF- ĸB  
 
The direct downstream effector of PI3K, Protein Kinase B/AKT plays a pivotal role in growth, 
survival and proliferation of cells via regulation of numerous downstream signals. Among these 
signals, the most commonly mentioned target is the nuclear factor-κB (NF- κB) pathway. 
Binding of inhibitor of ĸB (IĸB) to NF- ĸB causes localisation to the cytosol where it cannot 
regulate transcription. In the absence of IĸB, NF- ĸB is localised to the nucleus where 
transcription is induced. Initially, NF- ĸB was associated as a promoter of apoptosis. Agents like 
TNF-α, that induce apoptosis, also induce NF- ĸB (Beg and Baldwin, 1993, Beg et al., 1993), 
however, inhibition of NF- ĸB has been shown to potentiate apoptosis (Beg and Baltimore, 
1996, Wang et al., 1996). This is indicative NF- ĸB being an antiapoptotic molecule.  Inhibitor 
or ĸB kinase (IKK) degrades the active form, IKK-β via catalytic IKK-γ. Akt induces 
degradation of IĸB, the inhibitor of NF- ĸB by phosphorylation and IĸB kinase (IKK) 
activation, causing apoptotic inhibition (Romashkova and Makarov, 1999). The PI3K/Akt-
regulated NF- ĸB  activation, via IKK-β dependent mechanism is now well recognised (Shao et 
al., 2001, Sun et al., 2010) Tumour proliferation can be stopped via apoptosis or increasing 
sensitivity of these cells to anti-tumour agents by blocking NF-ĸB (Escarcega et al., 2007). 
 
1.2.8.2 PI3K/Akt and p53 crosstalk 
 
Integration of stress signals and survival pathways lead to cellular commitment to apoptosis. 
Apoptotic cell death is regulated via involvement of two proteins, p53 and Akt (Gottlieb et al., 
2002). The serine/threonine protein kinase B/Akt has an essential role in aversion of cell death 
(Lo and Cruz, 1995, Zhao et al., 2016). Various substrates regulated by Akt have been 
implicated in the inhibition of apoptosis and survival promotion (Lo and Cruz, 1995, Zhao et al., 
2016). Cellular stressors, such as damaged DNA, hypoxia and deregulation of oncogene 
expression, activate the tumour suppressor protein, p53. (Townsend and Tew, 2003, Berkholz et 
al., 2008, Qi et al., 2013).This transcription factor is central to regulating apoptosis. (Townsend 
and Tew, 2003, Crescencio et al., 2009, Sánchez et al., 2008). The cell death mechanism elicited 
by p53 may include direct transcriptional transactivation of various pro-apoptotic genes or 
transactivation-independent mechanisms. Akt and p53 are major, yet opposing components of 
cellular survival signalling pathways. The ultimate decision- death or survival may be attributed 
to a cross-talk between these two proteins. Studies have shown decreased expression of Akt in 
cells undergoing p53-dependent apoptosis (Sánchez et al., 2008, Velho et al., 2006). The ability 
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of Akt to directly impinge on the p53 pathway, quenching its apoptotic activity, is an attractive 
possibility. The Murine double minute 2, (Mdm2), onco-protein is an important physiological 
p53 regulator. It is a negative regulator of p53 and functions via p53 ubiquitinylation and 
induces rapid proteosomal degradation (Nakahara et al., 1994, Pierno et al., 1999, Qi et al., 
2013). Upon phosphorylation by Akt, Mdm2 efficiently translocates to the nucleus, where it 
binds to and degrades p53. Inspection of human Mdm2’s amino acid sequence, revealed two 
consensus sites, 166 and 186, phosphorylated by Akt (Park et al., 2008a). Thus, p53 function is 
inhibited via Akt-mediated Mdm2 phosphorylation, attenuating the apoptotic effects of p53 and 
cellular survival.  Furthermore, p53 exerts positive effects on the tumour suppressor gene, 
phosphatase and tensin homologue (PTEN) promoter. PTEN is responsible for inhibition of the 
PI3K/Akt pathway via PIP3 dephosphorylation (Chan et al., 2003b). 
 
1.2.9 Inflammatory status and cytokines  
 
The inflammatory response functions to protect against foreign bodies and pathogens. Its 
induction occurs via immune cells such as macrophages. These cells are activated and recruited 
and in turn regulate expression of cell adhesion proteins, chemokines and pro-inflammatory 
cytokines such as, TNF-α, IL-6, and IL-1 (Kulinsky, 2007). Studies suggest that the 
inflammatory response is closely associated with cancer; these include prostate, breast and lung 
carcinoma (Howe, 2007, Lin et al., 2001b, Dennis et al., 2002). TNF- α overexpression leads to 
increased tumour size (Suganuma et al., 1999). Data suggests that inhibition of PI3K signalling 
results in decreased pro-inflammatory cytokine production (Xie et al., 2014). These findings 
suggest the PI3K/Akt pathway has a potential therapeutic target for cancer and inflammatory 

















Atorvastatin (20mg, Aspavor, Pharmacia) was purchased from a local pharmacy (Dischem, 
Westwood). HepG2 cells were purchased from Highveld Biologicals (Johannesburg, SA). 
Tissue culture consumables were purchased from Lonza (Biowhittaker, Switzerland), and ATP 
and Caspase-Glo® -3/7, -8, and -9 assays, were purchased from Promega (Madison, USA). 
Western blot reagents were purchased from Bio-Rad (Hercules, CA, USA) and primary 
antibodies were purchased from Cell Signalling Technology, (Massachusetts, USA). Unless 








Figure 2.1: A summary of methodology used in all experiments in the study (prepared by 
author: Docrat, 2016) 
 
 
2.2 Cell culture and maintenance 
 
The main site for drug metabolism is the liver. The adherent, epithelial, HepG2 cells are a 
derivative of liver hepatocellular carcinoma from a 15year old Caucasian male. The general use 
of HepG2 cells involves assessment of bioactivation or metabolism of xenobiotics. Their 
morphology resembles the parenchymal cells of the liver, and they retain the majority of normal 
liver cell functions. Cells were maintained in 75cm3 culture flasks (37ºC, 5% CO2) (Figure 2.1). 
Complete culture media (CCM) [Eagle’s minimum essential medium (EMEM) supplemented 
with 1% L-glutamine, 1% penstrepfungizone, and 10% Foetal calf serum (FCS)], was provided 
for cell growth. Media was replenished every second day. Cells were sub-cultured at 90-100% 
confluency, rinsed thrice with 0.1M phosphate buffer saline (PBS) (5ml, 0.1M), and followed 
23 
 
by detachment using trypsin-EDTA (Lonza Biowhittaker) (2ml, 10-15min, 37 º C). Cells were 
monitored by the use of an inverted light microscope (Olympus IXSI; 20x magnification), when 
rounded, CCM was added in the ratio 2:1 to inactivate the trypsin. Agitation of flask allowed for 
detachment.  
 
The Trypan blue dye exclusion method is based on the principle that healthy cells possess intact 
cellular membranes, preventing dye entry whereas damaged/dead cells allow for staining to 
occur (Figure 2.2). The number of viable cells in suspension was determined using this method. 
All experiments were conducted in triplicate.  
 
Figure 2.2: Trypan Blue dye exclusion method (prepared by author: Docrat, 2016) 
 
2.3 Atorvastatin preparation  
 
The crystalline structure of Ato diminishes its solubility. The solubility of Ato was enhanced by 
altering its chemical structure to a more soluble amorphous form (Figure 2.3). The following 
steps were followed: 
  
a) Crushed Ato tablets (300mg) were completely dissolved in a non-hydroxlic solvent 
(1, 4-Dioxane) (50ml, 45-50ºC, 20min) until a clear solution was obtained. 
b) To precipitate the Ato calcium, the dissolved Ato was added (drop-wise) to a non-
polar anti-solvent (N-heptane) (200ml, 25-30 ºC, 20min). 
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c) Contents were stirred on a heat block (25-30 ºC) using a magnetic stirrer (2hours). 
d) Thereafter, the solvent was removed via filtration, and dried in an oven overnight 
(45-50 ºC) yielding amorphous Ato.  
This process yielded  85% of initial mass used. The Ato produced was dissolved in deionised 
water [1000µg/ml] and freeze-dried (VirTis 2.0). Thereafter, the freeze dried product was 
weighed, dissolved in dH2O, and filter sterilised [0.22 μM filter (Millipore)] to make up a stock 




Figure 2.3: Preparation of Atorvastatin from crystalline to amorphous form (PACE- Physician's 
Academy for Cardiovascular Education, 2016) 
 
2.4 Cell proliferation and metabolic activity 
 
2.4.1 MTT assay 
 
Cellular proliferation in HepG2 cells treated with Atorvastatin was assessed using the 
colorimetric methylthiazol tetrazolium dye reduction, [3, (4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyl tetrazolium bromide] (MTT) assay. The principle of this assay is dependent on the 
ability of metabolically active/viable cells to convert the yellow water-soluble MTT salt to its 
purple insoluble formazan product (Figure 2.4). This reaction is dependent on the activity of 
dehydrogenase enzymes and the redox potential of the cell. Dimethyl sulfoxide (DMSO) was 
used to dissolve the insoluble MTT crystals and a spectrophotometer (Bio-tek μQuant) was used 
25 
 
to measure absorbance values. The intensity of the formazan product is directly proportional to 
cellular viability and metabolic activity. 
 
Figure 2.4: Principle of MTT assay (prepared by author: Docrat, 2016) 
 
HepG2 cells were seeded (10 000cells/well) in a 96well-microtitre plate, and incubated with a 
range of Ato concentrations (200, 400, 600, 800, 1000, 1200µg/ml) in triplicate for 48h. 
Untreated control cells were incubated with CCM only. Thereafter, cells were incubated for 4h 
with the MTT substrate (5mg/ml in 0.1M PBS, 37ºC, 5% CO2). Following aspiration of 
supernatants, DMSO was added to all wells (100µl/well) and incubated for 1h. Optical densities 
(OD) were measured at 570nm with a reference of 690nm using a spectrophotometer (Bio-Tek 
µQuant). Data is represented as percentage cell viability (Figure 2.5), from which the IC50 (50% 
inhibitory concentration) was obtained.  







2.4.2 Treatment for subsequent assays 
 
An IC50 was extrapolated from the dose response curve and used to treat all subsequent assays. 
All treatments for assays subsequent to the MTT were conducted in 6-well plates. HepG2 cells 
were seeded (350 000cells/well) and allowed to grow to approximately 60% confluency. For 
each assay, untreated control and Ato-treated cells (IC50 value-678.8µg/ml) were prepared as 
three biological replicates, and incubated for 48h (37ºC, 5% CO2). CCM and treatments were 
replenished after 24h. Following incubation, the supernatants were aspirated and stored at -
80ºC. To ensure removal of any residual media, the cell sheet was rinsed with 0.1M PBS. 
 
2.4.3 The ATP quantification assay 
 
Intracellular levels of ATP were determined using the CellTiter-Glo® kit (Promega, United 
States, Madison, USA). The principle of the ATP quantification assay is based on 
bioluminescence. In the luciferase reaction, the presence of magnesium ions (Mg2+) and ATP 
facilitates the conversion of luciferin to oxyluciferin (Figure 2.6). As a result, energy is released 




Figure 2.6: Luciferase reaction where mono-oxygenation of luciferase occurs (prepared by 
author: Docrat, 2016) 
 
Cells were seeded in triplicate (20 000cells/well) into a microtiter luminometer plate.  
Following addition of 50µl CellTitre Glo™ reagent (Promega, Madison, USA) to each well, the 
plate was incubated in the dark at room temperature (RT) for 30min. This facilitated cell lysis 
and the luciferase-based reaction (Figure 2.5). The luminescent signal produced was read using 
a Modulus™ microplate luminometer (Turner Biosystems, USA). The ATP concentrations 






2.5 Oxidative status 
 
2.5.1 The thiobarbituric acid reactive substance assay  
 
Malondialdehyde (MDA) remains one of the most common biomarkers of lipid peroxidation 
(Ott et al., 2007). The thiobarbituric acid (TBA) reactive substance (TBARS) assay measures 
levels of MDA formed by lipid peroxidising systems. The procedure involves the condensation 
between TBA molecules and an MDA molecule (2:1), which yields a pink chromagen (Figure 
2.7). 
 
Figure 2.7: Principle of TBARS assay (prepared by author: Docrat, 2016) 
 
Following the 48h treatment, supernatants (200µl) were added to pre-labelled glass test tubes 
containing 200µl 2% phosphoric acid (H3PO4). A blank was used as a negative control to 
eliminate background absorbance.  To each tube, 7% H3PO4 (200µl), TBA/Butylated 
hydroxytoluene (BHT) (400µl), and HCl (1M) was added. HCl (3mM, 400µl) was added to the 
blank. A positive control, containing MDA (1µl) was prepared. Samples were vortexed and 
placed in a water bath (100ºC, 15min) and then allowed to cool (RT). After cooling, butanol 
was added (1500µl), vortexed and allowed to separate into two distinct phases. Thereafter, the 
upper butanol layer (100µl) was aliquoted in triplicate into a 96-well microtiter plate which was 







2.5.2 The Griess assay 
 
To determine the levels of nitric oxide (NO) metabolites produced, the standard protocol was 
used as described by (Reuter et al., 2010). The principle involves detection of nitrite (NO2-) 
present in solution via a diazotization reaction (Figure 2.8). 
 
Figure 2.8: Principle of Griess reaction (prepared by author: Docrat, 2016) 
 
Following preparation of standards with known concentrations (0-200µM) using stock sodium 
nitrate (200 µM), samples were pipetted into a 96-well microtiter plate (50µl, duplicate). 
Vanadium (III) Chloride (VCl3) (8mg/ml, 50µl), 2% Sulfanilamide (SULF) (25µl), and 
Naphthylethylenediamine dihydrochloride (NEDD) (0.1% in 5% HCl, 50µl) were added to each 
well respectively. The plate was incubated in the dark (30min, 37ºC), and absorbance was 
determined on a spectrophotometer (Bio-Tek µQuant), 540nm with reference wavelength 
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690nm. Data is represented as concentration (µM), determined by extrapolation from the 
standard curve. 
 
2.5.3 GSH-GloTM Glutathione assay 
 
Cellular glutathione levels are an indication of endogenous antioxidant capacity. In the presence 
of GSH, Glutathione- S- transferase (GST) catalyzes the conversion of a luciferin derivative to 
luciferin (Figure 2.9). The amount of glutathione present in the sample is directly proportional 
to the signal produced. 
 





Cellular GSH levels were analysed using the GSH-Glo™ Glutathione Assay kit as per 
manufacturer’s instructions (Promega, Madison, USA). Following treatment, cells were seeded 
in a white luminometer plate (20,000cells/well, triplicate in 0.1M PBS). Standards of known 
concentration (0-50µM) were prepared and pipetted in triplicate; from this a standard curve was 
generated. To each well GSH-Glo™ Reagent (50µl) was added followed by a brief agitation 
(30sec). The plate was incubated in the dark (RT, 30min). Thereafter, Luciferin Detection 
Reagent (100µl) was added followed by a second incubation in the dark (RT, 15min). The 
ModulusTM plate reader (Turner Biosystems, Sunnyvale, CA) was used to detect luminometric 
emission. Data is represented as concentration (µM), determined by extrapolation from the 
standard curve (Appendix 2).  
 
2.5.4 Cytochrome-P450 3A4 assay kit 
 
The effect of Ato on CYP3A4 activity in HepG2 cells was determined using the P450-Glo™ 
assay (Promega). CYP3A4 being a member of the cytochrome P450 family of proteins, has an 
essential role in oxidative metabolism of endogenous compounds and xenobiotics in the liver 
(Nakano et al., 2006). The principle of the P450-Glo™ 3A4 assay is based on a luminescent 
method for detection of CYP3A4 activity. Luminogenic CYP3A4 substrate is converted to 
luciferin by the CYP3A4 enzyme (Figure 2.10). The luciferase reaction produces a luminescent 
signal, which is directly proportional to CYP3A4 activity. Dexamethasone (Sigma, Aldrich, 
USA) was used as a positive control, as it’s known to induce CYP3A4 (Nakano et al., 2006). 
The reconstituted luciferin detection reagent was prepared as per manufacturer’s instructions. 
HepG2 cells were treated (48h) with Ato and dexamethasone (50µM in CCM) respectively. 
Cells were then seeded into a 96-well luminometer plate (50µl, 20,000cells/well, triplicate). 
Following incubation (in dark, RT, 4hours) with the luciferin-PFBE substrate (50µl/well), the 
luciferin detection reagent (50µl) was added and incubated (in dark, RT, 30min). The 
luminescence was detected with a Modulus™ microplate luminometer (Turner Biosystems, 




Figure 2.10: Reaction involved in the P450-Glo™ assay (prepared by author: Docrat, 2016)  
 
2.6 Cellular Death 
 
2.6.1 The lactate dehydrogenase assay 
 
Cell death/membrane damage was measured using the Lactate dehydrogenase (LDH) 
cytotoxicity detection kit (Roche, Germany). When cellular membrane integrity is compromised 
or lost, LDH, an otherwise stable cytosolic enzyme, is released into the extracellular space. This 
assay is colorimetric, and quantifies the level of LDH present in the supernatant of treated cells. 
This principle of this assay is based on a two-step enzymatic process. LDH acts as a catalyst in 
the conversion of lactate to pyruvate, which promotes reduction of NAD+ to NADH/H+ (Figure 
2.11). The newly formed NADH/H+ is used by a diaphorase to catalyze the reduction of a 




Briefly, 100µl supernatant was aliquoted in triplicate into a 96-well microtiter plate. Substrate 
mixture (100µl) consisting of a diaphorase/NAD+ catalyst and a sodium lactate/INT dye 
solution was added to each sample and incubated for 25min (RT). The optical density (OD) of 
the formazan product was read on a spectrophotometer (Bio-Tek µQuant) at 500nm. Data is 
represented as mean OD.    
 
Figure 2.11: Principle of LDH cytotoxicity assay (prepared by author: Docrat, 2016). 
 
2.6.2 Analysis of caspase activity 
 
Caspase activity was detected using the Caspase Glo® 3/7, Caspase Glo® 8, and Caspase Glo® 
9 Assay kits (Promega, Madison, USA). These assays have a homogenous and luminescent 
nature. Each assay kit contains their respective luminogenic substrates in buffer systems that 
have been optimised for caspase, cell lysis and luciferase activity. A luminescent signal is 





Figure 2.12: Overview of the caspase activity assay (prepared by author: Docrat, 2016) 
 
 Following the 48h treatment, cells were seeded in triplicate in a 96-well luminometer plate 
(20,000cells/well). The Caspase Glo® reagents (caspases -8, -9, and -3/7) were prepared 
according to manufacturer’s instructions (Promega) and were added to each sample (20µl). 
Following incubation in the dark (RT, 30min), the plate was read with a Modulus™ microplate 
luminometer (Turner Biosystems, Sunnyvale, USA) and data expressed in relative light units 
(RLU).  
 




The cytokine activity of Interleukin-6 (IL-6) and Tumour necrosis factor-alpha (TNF-α) were 
measured using the Human IL-6 and Human TNF-α ELISA kits (BD OptEIA™, USA). As per 
manufacturer’s instructions, a 96-well plate was coated (overnight) with IL-6 and TNF- α 
monoclonal antibodies (capture antibody diluted in coating buffer). Following 3 washes (1× 
detergent solution with ProClin™-150); ELISA Assay diluent (0.09% sodium azide, 12ml 
buffered protein base) was added to each well as a blocking agent (RT, 1hour). Standards were 
prepared (Figure 2.13) and added along with samples to appropriate wells (100µl), followed by 
a 2hour incubation (RT). Following 5 washes, working detector (Streptavidin-horseradish 
peroxide and Biotinylated anti-human monoclonal antibody) was added to each well and 
incubated in the dark (100µl, RT, 1hour). Thereafter, wells were washed seven times and TMB 
(3, 3’, 5, 5’-tetramethylbenzidine) One-Step Substrate Reagent was added. The plate was 
incubated in the dark (RT, 30min). Stop solution (1M phosphoric acid) was added (50µl/well). 
The absorbance was measured with a microplate reader (Bio-Tek µQuant, United States) at 
450nm with a reference wavelength of 570nm. Cytokine concentrations were determined by 
extrapolation from the standard curve (Appendix 3).   
 





Figure 2.14: ELISA Assay principle outlining configuration (prepared by author: Docrat, 2016)  
 
2.7 Western Blotting 
 
2.7.1 Protein extraction, quantification and standardisation 
 
HepG2 cells were treated as described in section 2.4.2 for protein isolation. CytobusterTM 
reagent (Novagen®, SA), supplemented with phosphatase and protease inhibitors (Roche, SA) 
was added to the cells (100µl/well) and placed on ice (30min). Cells were harvested via 
mechanical scraping and centrifuged (10 000xg; 4ºC, 10min). Supernatants were transferred to 




The bicinchoninic acid (BCA) assay was used to quantify the crude protein extract. This 
colorimetric assay is based on a two-step reaction (Figure 2.15). The first step involves 
reduction of Cu2+ ions to Cu+ by the peptide bonds in protein. The quantity of reduced Cu2+ is 
directly proportional to the amount of protein present in solution. The second step occurs when 
two BCA molecules chelate with a Cu+ ion, resulting in an intense purple colour that absorbs 
light at 562nm. 
 
 
Figure 2.15: Principle of BCA Assay (prepared by author: Docrat, 2016) 
 
Serial dilutions (0.2, 0.4, 0.6, 0.8 and 1.0mg/ml) were prepared from a bovine serum albumin 
(BSA) stock (1mg/ml in dH2O). From this a standard curve was constructed. Samples and BSA 
standards were transferred to a 96-well plate (25µl). Thereafter, the BCA working solution 
(200µl; 198µl BCA and 4µl CuSO4) was added to each well and incubated (30min, 37ºC). A 
spectrophotometer (BioTek µQuant) was used to read the absorbance at 562nm. The protein 
concentrations were determined by extrapolation from the standard curve (Appendix 4), and 






The separation of proteins, dependent on their size, is accomplished with sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Sample preparation involved 
denaturation of proteins with Laemmli buffer [dH2O, 10% SDS, β-mercaptoethanol, 0.5M Tris-
HCl (pH 6.8), glycerol, 1% bromophenol blue, (1:1)]. The tertiary structure of protein is 
maintained by disulphide bridges which are reduced by β-mercaptoethanol, whereas the anionic 
detergent SDS strongly binds to and denatures the protein. This produces protein with a 
uniform, negative charge that facilitates movement toward the positive electrode through the gel 
(Wilson, 2010). 
 
The molecular sieving properties of the gel allow the SDS-protein complexes to migrate through 
the resolving gel (Ding and Kaminsky, 2003). Polyacrylamide gels were prepared following set 
up of the Mini-PROTEAN 3 SDS-PAGE apparatus (Bio-Rad, USA) according to 
manufacturer’s instructions. The 7.5% resolving gel [1.5M Tris-HCl (pH 8.8), 10% SDS, 30% 
bis/acrylamide, dH2O, 10% APS, TEMED] was added between the glass plates, followed by a 
4% stacking gel [0.5M Tris-HCl (pH 6.8), 10% SDS, 30% bis/acrylamide, dH2O, 10% APS, 
TEMED]. The molecular weight marker (for identification of migrated proteins) and samples 
(35µl) were loaded into appropriate wells, followed by electrophoresis (150V, 1hour). Transfer 
buffer (192mM glycine, 25mM Tris, 20% methanol, pH 8.3) was used for equilibration of gels 
(RT, 10min).  
 
2.7.3 Protein transfer 
 
The transfer of proteins to a nitrocellulose membrane from a SDS-PAGE was done using 
electrophoresis [Trans-Blot® Turbo Transfer system (Bio-Rad)]. This allowed for the 
membrane to be probed for the antibody of interest. The procedure involved pre-soaking of 
nitrocellulose fibre pads in transfer buffer. This was followed by the assembly of a gel-sandwich 
(Figure 2.16) (fibre pad, nitrocellulose membrane, equilibrated gel, and a second fibre pad) 








Proteins express antigenic epitopes, which allow specific reactions to occur between target 
proteins and the primary antibody. Membranes were blocked (RT, 2hours) with 5% BSA in 
TTBS [Tris-buffered saline (TBS) consisting of 0.5% Tween20] to prevent nonspecific binding. 
The membranes were incubated with following primary antibodies (1:1 000 in 5% BSA) 
overnight (4ºC): NF-κB (9936T), Iκκ-β (2370), pAKT (4060), AKT (9272), pGSK-3(α/β) 
(8566), p53 (2527). Membranes were then washed with TTBS (5 times, 10min), followed by 
addition of horseradish peroxidase (HRP) conjugated secondary antibody [goat-anti rabbit IgG 
(H0913), 1:10 000 in 5% BSA] (RT, 1hour). This was followed by a final wash of membranes 
with TTBS (5 times, 10min). Chemiluminescent detection [Clarity western ECL substrate 
(BioRad)] facilitated visualisation of protein bands on the membrane on the Chemidoc™ 





2.7.5 Quantification of band density using Chemiluminescence 
 
The immunoblots were used to detect the proteins by using the enhanced chemiluminescence 
substrates (reagent A and B in 1:1 dilution). Following exposure, densitometric analysis was 
carried out on the Image Lab™ software (Bio-Rad) and measured as relative band density 
(RBD). 
 
2.7.6 Membrane re-probing 
 
Membranes were quenched with hydrogen peroxide (H2O2) (30min, 37ºC) to allow for probing 
with house-keeping protein β-actin. Following quenching, membranes were washed (3times, 
10min) and thereafter blocked (5% BSA, 2hours).  Membranes were then probed using HRP-
conjugated anti-β-actin (CS1615, Sigma). Results are normalised as RBD of proteins of interest 
divided by RBD of β-actin.  
     
2.8 Statistical Analysis 
 
Data analysis was performed using the GraphPad prism V5.0 software (GraphPad Software Inc., 
La Jolla, USA). Statistical comparisons between results were made using either the one-way 
analysis of variance (ANOVA) followed by a Bonferroni test for multiple group comparison 
(data is presented as 95% CI) or the unpaired t-test with Welch correction (mean ± standard 







RESULTS               
 
3.1 Cell proliferation and metabolic activity 
 
3.1.1 Cell Viability 
 
The effect of Ato on cell proliferation was measured by assessing the metabolic activity in 
HepG2 cells using the MTT assay. Following a 48h incubation period with serial dilutions of 
Ato (0-1200µg/ml), a dose-dependent decline in cell viability was observed. An IC50 (50% 
inhibitory concentration) value was obtained at 678.8µg/ml, and used in all subsequent assays 
(48hr incubation).  
 







3.1.2 Intracellular ATP levels 
 
The level of cellular ATP was determined (luminometric assay). In comparison to the control 
(2, 6×106 RLU ±8×104 RLU), Ato significantly reduced ATP levels (5, 1×105 RLU ±1, 3×104 
RLU; p=0.005) (Figure 3.2).  
 
 
Figure 3.2: Level of intracellular ATP was significantly reduced in Ato-treated cells when 
compared to control cells (**p≤0.005). RLU: relative light units 
 
3.2 Oxidative status 
 
The effects of Ato induced oxidative stress in HepG2 cells was determined by measuring lipid 
peroxidation, levels of nitrites, glutathione (GSH), and CYP3A4 activity.    
 
3.2.1 Lipid Peroxidation 
 
The level of MDA, a lipid peroxidation biomarker, was assessed with the TBARS assay. MDA 
levels were significantly reduced following Ato exposure compared to the control (1.7×10-1µM 





Figure 3.3: Level of malondialdehyde in Ato-treated cells is significantly reduced (*p≤0.05). 
 
 
3.2.2 Level of nitrates and nitrites 
 
Nitrite and nitrate levels were measured using the Griess assay. The nitrite/nitrate levels were 
significantly increased by Ato as compared to the control (14.98µM ± 1×10-5µM vs. 12.6µM ± 





Figure 3.4: Extracellular nitrite and nitrate levels were increased in cells exposed to Ato 
(**p≤0.005). 
 
3.2.3 Glutathione concentration 
 
The intracellular concentration of GSH was determined using the GSH-Glo™ Glutathione 
assay. GSH concentrations in HepG2 cells were significantly decreased by Ato treatment as 
compared to the control (1.24µM ± 5.2×10-3µM vs. 3.14µM ± 5.6×10-2µM; p=0.0003) (Figure 




Figure 3.5: Glutathione concentrations significantly decreased in HepG2 cells after exposure to 
Ato (**p≤0.005) 
 
3.2.4 Cytochrome P450 3A4 Activity 
 
 Induction of CYP3A4 enzyme activity was measured using luminometry. Dexamethasone (dex; 
positive control) and Ato treated cells significantly increased CYP3A4 activity in comparison to 
the control (p=0.0079; control vs. Dex: 95% CI, -6.2×102 RLU to -1.3×102 RLU; control vs. 





Figure 3.6: CYP3A4 activity in HepG2 cells was significantly induced by Ato in comparison to 
the control (*p≤0.05). RLU: relative light units. Dex: Dexamethasone 
 
3.3 Cellular Death 
 
3.3.1 Extracellular LDH level 
 
The level of extracellular LDH was measured as a marker of compromised cell membrane 
integrity. Ato treated cells had increased LDH levels in comparison to untreated cells (1.27 units 




Figure 3.7: Level of extracellular LDH in ato treated cells (**p≤0.005). OD: Optical density. 
 
3.3.2 Analysis of caspases 
 
Apoptotic cell death was evaluated by quantifying caspase activity using the Caspase-Glo® 
assays. Atorvastatin significantly increased the activities of caspase- 3/7 (4.8×105 RLU ± 
1.3×104 RLU vs. control: 1.7×105 RLU ± 2.5×104 RLU; p=0.0003) and -9 (2.6×105 RLU ± 
2.6×103 RLU vs. control: 2.3×105 RLU ± 1.4×103 RLU; p<0.0001) in comparison to the control. 
However, caspase-8 activity was significantly decreased by Ato compared to untreated cells 






Figure 3.8:  Caspase- 3/7 (**p≤0.005), and -9 activities were significantly increased 
(***p≤0.0001), and capase-8 activity was significantly decreased in Ato treated cells 
(**p≤0.005). RLU: relative light units. 
 
3.3.3 Cytokine analysis 
 
Next, the caspase-8 change was investigated as to its relation to the cytokine concentration of 
TNF-α, as well as the effect of Ato on IL-6. A significant decrease was seen in TNF-α following 
ato treatment as compared to the control (14.69±1.57pg/ml vs. control: 18.11±1.57pg/ml; 
p=0.0105) (Figure 3.9 A). However, the IL-6 concentration was increased in treated cells 




Figure 3.9: Mean cytokine concentration of (A) TNF-α was significantly decreased (*p≤0.05), 
however IL-6 was elevated significantly (B) (**p≤0.01).  
 
3.4 Western Blotting  
 
Due to the increased caspase -3/7 and -9 activity, protein expression of molecules involved in 
signalling pathway that promotes cell survival and growth was investigated. Western blot 
analysis confirmed significant decreases in both pAKT (0.41×10-1 RBD±6.7×10-2 RBD vs. 
control: 8.3×10-1 RBD±5.2×10-2 RBD; p=0.0035) (Figure 3.10 A) and AKT (5.1×10-1 
RBD±1.2×10-2 RBD vs. control: 1.5RBD±1.6×10-1 RBD; p=0.0077) in response to Ato 
treatment as compared to the control (Figure 3.10 B). This confirms that Ato inhibits the Protein 






Figure 3.10: Protein expression of (A) pAKT (**p≤0.005), and (B) AKT (*p≤0.05) in HepG2 
cells was significantly decreased following ato exposure. RBD: Relative band density 
 
Next, we investigated protein expression of the downstream targets of AKT. Significant 
increases in pGSK3-(α/β) (2.1×10-1 RBD±3.3×10-2 RBD vs. control: 1.3×10-1 RBD±2.0×10-2 
RBD; p=0.0338) (Figure 3.11 A) and p53 (5.8×10-1 RBD±6.4×10-2 RBD vs. control: 2.0×10-1 






Figure 3.11: Protein expression of (A) pGSK3-(α/β) (*p≤0.05) and (B) p53 (**p≤0.005) was 
significantly increased by Atorvastatin. RBD: Relative band density 
 
Anti-apoptotic targets of AKT: NF-κB, and IKK-β, were analysed for protein expression. 
Atorvastatin exposure led to significant decreases in both NF-κB (8.7×10-1 RBD±1.3×10-1 RBD 
vs. control: 1.4 RBD±1.2×10-1 RBD; p=0.013) (Figure 3.12 A) and IKK-β (3.8×10-2 
RBD±8.3×10-3 RBD vs. control: 3.2×10-1 RBD±4.6×10-2 RBD; p=0.0094) expression in HepG2 





Figure 3.12: Protein expression of (A) NF-κB (*p≤0.05) and (B) IKK-β (*p≤0.05) in treated 
















Statins are the most commonly prescribed drugs for treatment of cardiovascular disease 
(Watcharasit et al., 2002). Atorvastatin is the most frequently prescribed statin as it is well-
tolerated and has a lower therapeutic dose in comparison to lovastatin, simvastatin and 
cerivastatin. Clinical trials have demonstrated the high benefit-risk ratio of atorvastatin (van 
Weeren et al., 1998). Recent studies suggest that statin use results in increased survival rates of 
cancer patients (Nielsen et al., 2012). 
 
Tumourigenesis is a result of aberrant cellular growth accompanied by low apoptotic rates 
(Luzzi and Marletta, 2005). The process of apoptosis is either aberrant or inhibited in cancer 
cells (Schuler and Green, 2001). Cancerous cells are able to evade the apoptotic cascade, 
resulting in their uncontrolled growth (Hanahan and Weinberg, 2000). The effect of statins on 
cancer cells have been studied from as early as the 1990’s (Agarwal et al., 1999). However, the 
molecular mechanism involved in their apoptotic effects remains a major focus of investigation. 
 
In this study, we evaluated the effects of Ato on hepatocellular carcinoma (HepG2) cells. The 
MTT results depicted decreased dose-dependent cell viability (Figure 3.1) and reduced 
metabolic activity (Figure 3.2) by Ato in HepG2 cells. The enzyme HMGCR is responsible for 
the conversion of HMG-CoA to mevalonate. The compromised metabolic function may be a 
result of statin-induced HMGCR inhibition (Stancu and Sima, 2001); acetyl-coA accumulates in 
the mitochondria and is converted to citrate which is pumped to the cytosol (Oh et al., 2012). 
The conversion of dissolved MTT salts to its insoluble formazan product occurs via 
dehydrogenase enzymes (Slater et al., 1963). This may result in diminished reducing 
equivalents, hence, decreased conversion of MTT and production of intracellular ATP. Tumour 
cells promote ATP production by mitochondrial oxidative phosphorylation, which may be 
shifted to glycolysis for additional ATP production (Kim et al., 2008). Inhibition of HMGCR by 
statins limits not only cholesterol synthesis, but other vital isoprenoid intermediary metabolites, 
such as electron transport chain proteins like ubiquinone. The observed decrease in ATP levels 
(Figure 3.2) may be a result of impaired glucose uptake and reduced mt function due to the 




Numerous studies suggest that cancer cells experience increased oxidative stress associated with 
oncogenic transformation, changes in metabolic activity, and elevated levels of ROS, which 
promotes tumour progression and development (Behrend et al., 2003, Hileman et al., 2001, 
Kang and Hamasaki, 2003, Toyokuni et al., 1995). During cholesterol metabolism, Ras and Rac 
activation by geranylgeranylpyrophosphate (GGPP) stimulates NADPH oxidase, which is 
responsible for ROS production (Behrend et al., 2003, Wang et al., 2008, Wassmann et al., 
2002, Yeganeh et al., 2014). Malondialdehyde was used as a measure of oxidative stress. The 
significant decrease in MDA (Figure 3.3) indicates decreased lipid peroxidation. The decreased 
ROS production may be a consequence of HMGCR inhibition. Furthermore, metabolically 
active mitochondria produce ROS via oxidative phosphorylation (Liou and Storz, 2010). The 
observed decrease in ATP concentration indicates impaired activity of mt ETC, correlating with 
diminished ROS production. Additionally, growth factors and cytokines such as TNF-α are 
known to stimulate ROS production (Lo and Cruz, 1995). The decreased level of TNF-α (Figure 
3.9 A) is in agreement with the lower levels of ROS in treated cells.  
 
The elevated levels of ROS in tumour cells, result in their acquisition of a concomitant robust 
antioxidant capacity, which leads to cancer cell growth (Zhao et al., 2016). Overproduction of 
GSH is well documented in various cancers (Townsend and Tew, 2003). During GSH 
production, NADPH is essential for the enzymatic function of glutathione reductase which 
converts GSSG to GSH (Berkholz et al., 2008). The decreased GSH concentration (Figure 3.5) 
is most likely a result of its NADPH-dependent mechanism, and correlates with diminished 
ROS levels. 
 
Atorvastatin is metabolised by the CYP3A4 enzyme during first pass metabolism (Park et al., 
2008a). During the catalytic cycle, one-electron transfer reactions take place which lead to the 
continuous formation of ROS (Puntarulo and Cederbaum, 1998). Interestingly, Ato decreased 
ROS levels despite the significant increase in CYP3A4 activity (Figure 3.6). The increase in 
CYP3A4 activity may be attributed to biotransformation of Ato. 
 
In contrast to this study, other studies indicate that cancer cell death occurs via enhanced 
oxidative stress (Crescencio et al., 2009, Sánchez et al., 2008, Qi et al., 2013). The ROS-
mediated cell death in these studies may be due to the presence of calcium in Ato. Studies 
which support the central role of calcium depicted altered calcium homeostasis following statin 
treatment (Nakahara et al., 1994, Pierno et al., 1999, Sirvent et al., 2005). Furthermore, statins 
have been shown to induce Ca2+ -dependent mt permeability transition (Velho et al., 2006).  In 
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this study, the amorphous form of Ato has a lower calcium level which corresponds to the lower 
level of ROS production. 
 
The prenylation of Rho GTPases result in inhibition of endothelial NOS (eNOS) (Stryjkowska-
Gora et al., 2015). Oxidation of L-Arginine to L-citrulline is catalysed by the NOS enzyme to 
generate NO (Luzzi and Marletta, 2005). Zhou et al., (2016) showed that high levels of NO 
inhibit the metastatic cascade in HCC (Zhou et al., 2016). Atorvastatin and simvastatin have 
been shown to decrease Rho prenylation in vascular smooth muscle cells (Blanco-Colio et al., 
2002). This study indicates significantly increased NO metabolite production (Figure 3.4), 
which may be attributed to the ability of Ato to decrease Rho prenylation. This result is in 
agreement with Kanugula et al., (2014) where statins were shown to induce cell death by 
increased NO and diminished ROS (Kanugula et al., 2014). Taken together, these results 
provide evidence of the anti-proliferative and antioxidant effects of Ato in HepG2 cells, which 
are mediated by decreased ROS and increased NO production.   
 
Cellular membranes are lipid in nature, allowing cholesterol-mediated lipid interactions to occur 
(Eggeling et al., 2009). The observed increase in LDH (Figure 3.7) may be due to the lipophilic 
nature of Ato. As a result, membrane damage and LDH leakage occurred. Cytokine-receptor 
binding promotes lipid PI3K activation at the cell membrane (Cantley, 2002). Activation of the 
Ras protein GTPase promotes PI3K activation of Akt to the lipid-rich membrane. Aberrant 
PI3K activity has been associated with various cancers (Chang et al., 2003, Fry, 2001, Jucker et 
al., 2002, Krasilnikov et al., 1999, 2010, Lin et al., 1999, Lin et al., 2001a). The decreased 
protein expression of both the active, phosphorylated form of AKT (pAKT) and total AKT 
(Figure 3.10) validates the LDH result. Atorvastatin inhibition of HMGCR prevents Ras-
mediated PI3K activation which may lead to AKT inhibition. Our results are in agreement with 
a study that showed Ato-inhibition of Protein kinase B signalling in pancreatic cancer cells 
(Mistafa and Stenius, 2009). 
 
Caspases are intracellular proteases that initiate apoptosis. Akt is known to phosphorylate pro-
apoptotic members, resulting in caspase inhibition (Zhou et al., 2000). Our study indicates that 
Ato increased caspase -9 and -3/7 activity (Figure 3.8) which correlates with the decreased 
protein expression of Akt. The observed decrease in the extrinsic caspase-8 (Figure 3.8) 
indicates that Ato induces mitochondrial-mediated apoptosis. This result is in agreement with 
Aprigliano et al., where Ato was shown to induce apoptosis via the caspase-9-dependent 
pathway in hepatic stellate cells (Aprigliano et al., 2008). The decrease in TNF- α cytokine 
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levels (Figure 3.9 A) by Ato may prevent ligand receptor binding at the cell membrane. This 
could explain why the extrinsic pathway was not activated as caspase-8 activity is mediated by 
this binding. However, it has been shown that with longer incubation periods, statins may 
induce caspase-8 activation (Minichsdorfer and Hohenegger, 2009). 
 
Glycogen synthase kinase-3, a downstream target of Akt, plays an integral role in cell 
proliferation and apoptosis (Jope and Johnson, 2004). Apoptosis is promoted by GSK-3 via 
activation of tumour suppressor protein, p53, as well as inactivation of cell survival promoters 
like cyclin D1 by phosphorylation (Watcharasit et al., 2002). Protein kinase B/Akt activation 
leads to GSK-3 inhibition (van Weeren et al., 1998). The observed upregulation of pGSK-3(α/β) 
(active form) (Figure 3.11 A) correlates to the decreased Akt expression in treated cells. One of 
the mechanisms involved in apoptotic inhibition by Akt involves enhancement of Mdm2, which 
promotes p53 degradation (Gottlieb et al., 2002). The noted increase in p53 protein expression 
(Figure 3.11 B) may be attributed to inhibition of Mdm2. These results agree with a study 
showing pre-treatment with statins attenuates activity of cytostatic drugs, resulting in Akt 
inhibition and p53 stabilisation in HepG2, A549 and H1299 cells (Roudier et al., 2006). Schuler 
et al., (1999) showed that p53 potentiates apoptosis via cytochrome-c release (Schuler and 
Green, 2001). Together, the increased p53 expression as well as caspase-9 and -3/7 activity 
confirm mitochondrial-mediated cell death. Furthermore, the increased p53 expression may 
promote the tumour suppressor gene PTEN, resulting in the noted downregulation in Akt. Our 
results are in agreement with a study that shows modulation of PTEN expression with a 
concomitant decrease in Akt following treatment with (Miraglia et al., 2012) . 
 
The anti-apoptotic and anti-inflammatory protein NF-κβ, and its active form, IKK-β, are 
downstream Akt substrates (Shao et al., 2001, Sun et al., 2010). Protein expression of NF-κβ 
and IKK-β (Figure 3.12) was significantly downregulated by Ato. This correlates with the 
decreased Akt expression. Although TNF-α plays a role in caspase activity, it is known to 
induce proinflammatory NF-κβ (Beg and Baldwin, 1993, Beg and Baltimore, 1996). 
Additionally, the decreased NF-κβ and IKK-β expression may be a result of the decreased TNF-
α cytokine level (Figure 3.9 A), thus indicating the anti-inflammatory effect of Ato. This result 
is consistent with a study by Rashidian et al., (2016), that showed the anti-inflammatory effect 
of Ato via decreased TNF-α levels and concomitant NF-κβ inhibition (Rashidian et al., 2016).  
 
Protein Kinase B is known to phosphorylate and inhibit FoxO (Kim et al., 2008). Evidence 
suggests the relation between IL-6 cytokine activity and STAT-3 mediated import of FoxO to 
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the nucleus, where its accumulation coincides with increased inhibitor or kappa-B kinase (IKK) 
and p27 expression. (Oh et al., 2012).  Atorvastatin increased IL-6 activity (Figure 3.9 B) which 
validates the decreased IKK-β expression; this may be a result of activation of IKK (inhibitor or 
kappa-B kinase) by FoxO. Evidence suggests that repressed PI3K/Akt activity leads to 
concomitant FoxO induction (Coussens and Werb, 2002). The Wnt pathway controls cell cycle 
entry C-myc activation via activation of c-Myc, cyclin D and p53 (Kanugula et al., 2014, Sun et 
al., 2010, Wassmann et al., 2002, Xie et al., 2014). Progression of the cell cycle through the 
G0/S phase may result through convergence of the PI3K/Akt/mTOR and Wnt pathways (Zhang 
et al., 2011). The decreased Akt (Figure 3.10) may have led to increased FoxO-mediated p53 
(Figure 3.11 B) through p21 and p27 activation.  
 
Previous studies have implicated the potential use of statins as anticancer agents (Chan et al., 
2003a, Crescencio et al., 2009, Malenda et al., 2012). Simultaneously, it is well known that the 
PI3K/Akt signalling pathway is a major molecular target for chemotherapy (Chang et al., 2003). 
Collectively, the data suggests that Ato induces HepG2 cell death, as well as provides 
















5.1 Limitations of study 
 
The use of one cell line, the molecular mechanism depicted by this study could be looked at in 
other cancerous cell types. 
The results obtained from this in vitro study may differ from an in vivo study. This could be 
attributed to the cells being isolated. An in vivo study will allow for a truer result as it would 





The present study showed that Ato possessed potent apoptotic potential through its ability to 
reduce cholesterol and isoprenoid levels. This study has shown that Ato regulates HepG2 cell 
growth and proliferation by exerting antioxidant effects, which include decreased ROS and 
increased NO metabolite production. The mitochondrial mediated apoptotic pathway was 
activated via direct inhibition of the PI3K/Akt signalling pathway. Furthermore, Ato induced 
anti-inflammatory effects in HepG2 cells via inhibition of the NF-κB pathway. 
 
This study provides evidence of the potential usage of Atorvastatin in chemotherapy. However, 
further studies are required in other cancerous cell lines to ensure consistency of Ato’s effects. 
Atorvastatin-induced cell death via its involvement in the Pi3k/Akt/mTOR/Wnt pathways 
creates an avenue for further research. Prior to the use of statins in cancer treatment, it is 
essential to investigate the drug in vivo, as well as perform randomised clinical trials. It may 
also be interesting to determine the effect of statins in combined therapy, if they are found to be 
inefficient as monotherapy. It can be concluded that Ato shows potential as a therapeutic 
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0 0.00 0.74 100 
200 2.30 0.63 84 
400 2.60 0.50 67 
600 2.78 0.42 57 
800 2.90 0.34 46 
1000 3.00 0.27 36 







































ELISA standards- TNF-α 
 
Standards were prepared using a stock concentration of 116ng. 
 















ELISA standards- IL-6 
 
Standards were prepared using a stock concentration of 18ng. 
 















ELISA standards- IL-1β 
 
Standards were prepared using a stock concentration of 25ng. 
 

















Figure 5: No significant change in IL-1β between control and treated cells 
 
 
ELISA standards- IL-10 
 
Standards were prepared using a stock concentration of 13ng. 
 














Figure 6: Standard curve generated from IL-10 standards. 
 
The concentrations for TNF-α, IL-6, IL-1β, and IL-10 were prepared and used to 
generate the standard curves above. The curve was extrapolated and the equations 
displayed on the graphs were used to determine the respective cytokine concentrations 










Protein quantification and standardisation 
 
 Bovine serum albumin (BSA) (mg/ml) 
Standard 0 0.2 0.4 0.6 0.8 1 
OD1 0.108 0.412 0.623 0.754 1.099 1.231 
OD2 0.105 0.455 0.587 0.746 1.025 1.276 
OD3 0.105 0.444 0.670 0.756 0.947 1.186 







Figure 8: Standard curve generated from BSA standards. 
 
 
 
 
 
 
 
 
 
 
  
